Board of Directors
Scientific Advisory Board
Events & Webcasts
Harnessing insights from live patient tumor cells to develop better therapeutic options for cancer patients
Our proprietary CELsignia platform analyzes oncogenic pathways in live tumor cells.
This enables us to discover cancer drivers molecular tests cannot identify.
We translate our discoveries into the development of new therapeutic options for cancer patients.
Gedatolisib Press Release
Offering hope to cancer patients means finding the driver of their cancer.
Genomic testing cannot diagnose many patients’ cancer driver, limiting treatment options.
CELsignia analyzes a patient’s own live tumor cells to reveal complex oncogenic activity.
These insights reveal new cancer drivers so patients can be more precisely matched to the right targeted therapy.
Celcuity is now developing, directly and through collaborations, targeted therapies to treat these patients.